Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting

ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate

Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally well-tolerated at all doses tested

Less frequent dosing regimen, a shift from five daily infusions to two infusions per three-week cycle, is being evaluated as both a single agent and in combination with pembrolizumab in patients with cutaneous melanoma in ARTISTRY-6. Preliminary data readouts from the cohorts are expected in 2025

WALTHAM, Mass. and DUBLIN, May 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today shared data from ARTISTRY-3, a clinical trial designed to evaluate the effects of less frequent intravenous dosing (LFIV) of nemvaleukin alfa (nemvaleukin), in advance of the American Society of Clinical Oncology (ASCO) annual meeting taking place May 31-June 4 in Chicago.

Nemvaleukin, Mural’s lead candidate, is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose native IL-2 while mitigating the cytokine’s hallmark toxicities. In ARTISTRY-1, the company sought to recapitulate the results of high-dose IL-2 by mimicking its dosing regimen with five daily intravenous (IV) infusions (days 1-5) per three-week cycle. In the ARTISTRY-3 trial, the company evaluated escalating LFIV infusions, all of which were generally well tolerated. The safety profile in all dosing schedules evaluated was consistent with nemvaleukin’s known mechanism of action, and no dose limiting toxicities were observed. Despite administering higher doses per three-week dosing cycle than in previous trials evaluating nemvaleukin with daily infusions, no new safety signals were identified. The desired pharmacodynamic (PD) effects were also seen across all evaluated doses. Expansion of antitumor CD8+ T cells and natural killer (NK cells) was observed concurrent with minimal expansion of immunosuppressive regulatory T cells (T_regs).